Details

Autor(en) / Beteiligte

• Koot, Anna
• Soares, Paula
• Robenshtok, Eyal
• Locati, Laura D.
• de la Fouchardiere, Christelle
• Luster, Markus
• Bongiovanni, Massimo
• Hermens, Rosella
• Ottevanger, Petronella
• Geenen, Frans
• Bartѐs, Beate
• Rimmele, Harald
• Durante, Cosimo
• Nieveen-van Dijkum, Els
• Stalmeier, Peep
• Dedecjus, Marek
• Netea-Maier, Romana

Titel

Position paper from the Endocrine Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) on the management and shared decision making in patients with low-risk micro papillary thyroid carcinoma

Ist Teil von

• European journal of cancer (1990), 2023-01, Vol.179, p.98-112

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The incidence of differentiated thyroid cancer (DTC) has been increasing worldwide, mostly, as an increase in the incidental detection of micro papillary thyroid carcinomas (microPTCs), many of which are potentially overtreated, as suggested by the unchanged mortality. Several international guidelines have suggested a less aggressive approach. More recently, it has been shown that active surveillance or minimally invasive treatments (MIT) are good alternatives for the management of these patients. In this context, patient participation in the decision-making process is paramount. The Endocrine Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) has undertaken the task to establish consensus and define its position based on the scientific evidence concerning, 1) the current state of diagnostic and management options in microPTCs, including the current opinion of physicians about shared decision making (SDM), 2) the available evidence concerning patients' needs and the available decision instruments, and 3) to provide practical suggestions for implementation of SDM in this context. To improve SDM and patients' participation, knowledge gaps and research directions were highlighted. •New management approaches for patients with low-risk microPTC have been introduced.•For all available options, scientific evidence is weak, resulting in clinical equipoise.•SDM to carefully discuss these treatment options with patients is paramount.